Muscle inactivity due to injury or disease results in muscle atrophy. The molecular mechanisms contributing to muscle atrophy are poorly understood. However, it is clear that expression of atrophy-related genes, like Atrogin-1 and MuRF-1, are intimately tied to loss of muscle mass. When these atrophy-related genes are knocked out, inactive muscles retain mass. Muscle denervation stimulates muscle atrophy and Myogenin (Myog) is a muscle-specific transcription factor that is highly induced following muscle denervation. To investigate if Myog contributes to muscle atrophy, we have taken advantage of conditional Myog null mice. We show that in the denervated soleus muscle Myog expression contributes to reduced muscle force, mass, and cross-sectional area. We found that Myog mediates these effects, at least in part, by regulating expression of the Atrogin-1 and MuRF-1 genes. Indeed Myog over-expression in innervated muscle stimulates Atrogin-1 gene expression and Myog over-expression stimulates Atrogin-1 promoter activity. Thus, Myog and the signaling cascades regulating its induction following muscle denervation may represent novel targets for therapies aimed at reducing denervation-induced muscle atrophy.
D
isease and injury of the neuromuscular system often results in lost muscle activity which leads to muscle atrophy. This atrophy is a consequence of catabolism of muscle proteins. Although muscle catabolism can be beneficial in times of need, its long term consequences can be dire. Interestingly, not all muscles atrophy to the same extent in response to inactivity. Muscles enriched with slow fiber types, such as the soleus muscle, atrophy to a greater extent than those with predominantly fast fiber-types [Grossman et al., 1998 ]. During soleus muscle atrophy, slow fibertype myosin heavy chain isoforms are lost, while faster type II isoforms are increased [Grossman et al., 1998 ].
One approach for identifying ways of preventing or reversing the detrimental consequences of muscle atrophy is to identify mechanisms underlying this process. It is hoped that these mechanisms may suggest novel strategies for intervention. In general, muscle atrophy is accompanied by activation of the ubiquitin-proteosome system [Cao et al., 2005; Ventadour and Attaix, 2006] . In this system proteins are targeted for degradation by being polyubiquinated and then degraded by the 26S proteosome.
Two ubiquitin-protein ligases, Atrogin-1 (Fbxo32/MAFbx) and MuRF-1 (Trim63), are induced in atrophying skeletal muscle and knockout mice lacking either of these ligases exhibit reduced denervation-dependent muscle atrophy [Bodine et al., 2001a; Gomes et al., 2001] . Although muscle atrophy is most dramatic around 2-4 weeks following muscle denervation, the expression of Atrogin-1 and MuRF-1 transcripts peak around 3 days postdenervation when the rate of muscle weight loss is most rapid [Sacheck et al., 2007] .
A number of studies have shown that activation of the IGF-1/ PI3K/AKT signaling pathway can stimulate muscle hypertrophy and inhibition of this pathway can lead to muscle atrophy [Bodine et al., 2001b; Rommel et al., 2001; Stitt et al., 2004] . This pathway was also shown to regulate Atrogin-1 expression via phosphorylation of FoxO transcription factors [Sandri et al., 2004; Sandri et al., 2006] . In addition, denervation-dependent suppression of PGC-1a (peroxisome proliferator-activated receptor g-coactivator 1a) expression stimulates muscle atrophy by relieving repression of Atrogin-1 expression [Sandri et al., 2006] . Finally, cytokines, such as TNF-like weak inducer of apoptosis (TWEAK), can stimulate muscle atrophy via a NF-kB signaling pathway that regulates MuRF-1 expression [Mittal et al., 2010] .
We reasoned that muscle-specific transcription factors that are also regulated in an activity-dependent manner may be good candidates for regulating genes, like Atrogin-1 and MuRF-1, which stimulate muscle atrophy. One such gene encodes Myogenin (Myog), a basic helix-loop-helix transcription factor that is necessary for muscle differentiation and is regulated by muscle activity [Eftimie et al., 1991; Hasty et al., 1993] . Indeed, while this article was in preparation, it was reported that Myog contributes to denervationdependent muscle atrophy by controlling expression of atrophyrelated genes like MuRF-1 and Atrogin-1 [Moresi et al., 2010] . However, these studies were confined to relatively fast muscles and did not investigate if Myog also regulates atrophy of slow muscles. Furthermore, these previous studies did not investigate if any of the consequences of muscle denervation and Myog deletion were a result of compensation by the contralateral innervated muscle or due to increase satellite cell proliferation and fusion.
Here, we report that Myog contributes to denervation-dependent atrophy of the slow soleus muscle via regulated expression of Atrogin-1 and MuRF-1 gene expression. We demonstrate that this effect is intrinsic to the denervated hindlimb and not a result of compensation by the contralateral limb or by increased myoblast proliferation and fusion in the Myog null denervated muscle. Our data suggest that denervation-induced muscle atrophy, and its regulation by Myog, is more dramatic in the predominantly slow soleus muscle compared to the fast extensor digitorum longus (EDL) muscle. We go on to show that attenuation of muscle atrophy by Myog is also reflected in muscle function (force generation). Finally, consistent with the idea that Myog directly regulates Atrogin-1 and MuRF-1 gene expression, we show that all three genes are coordinately suppressed by muscle electrical activity and that distal E-boxes in the Atrogin-1 promoter are most effective in mediating Myog-dependent promoter regulation. These data, along with those of Moresi et al., 2010 , suggest Myog induction in denervated muscle contributes to the development of muscle atrophy via regulated expression of ubiquitin ligases Atrogin-1 and Murf-1.
MATERIALS AND METHODS

ANIMALS AND TAMOXIFEN-INDUCED RECOMBINATION
All animal studies were approved by the University of Michigan Committee on Use and Care of Animals. Myog conditional knockout mice (Myog flox/flox ;CAGG-CreER TM ) were described previously [Knapp et al., 2006] . To induce recombination in Myog conditional knockout mice, 1 mg of tamoxifen suspended in sunflower seed oil was injected intraperitoneally into adult mice for five consecutive days followed by a 2 day rest and then repeated. Tamoxifen-induced recombination should result in deletion of exon 1 in the Myog gene [Knapp et al., 2006] . Myog exon 1 deletion was confirmed by polymerase chain reaction (PCR) using genomic DNA isolated from EDL muscles of Wt (wild type) and Myog flox/flox ;CAGG-CreER TM tamoxifen injected mice. EDL muscles were dissected, lysed in 100 ml of 25 mM NaOH, 0.2 mM EDTA at 958C for 20 min and then buffered by addition of an equal volume of 40 mM Tris-HCl (pH 7.8).
Samples were vortexed briefly and centrifuged at 2,000 rpm for 10 min. One microliter of lysed muscle containing genomic DNA was used for each PCR reaction. To test for tamoxifen-induce recombination, primers were designed to amplify a genomic DNA fragment spanning the majority of exon 1 (forward primer 5 0 CTACCAGGAGCCCCACTTCTATGATG) and a portion of exon 2 (reverse primer 5 0 AGGAGGCGCTGTGGGAGTTGC). Amplification of genomic g-actin DNA was performed with forward 5 0 AGAAGAA-ATCGCCGCACTCGTCAT and reverse 5 0 CCTCTTGCTCTGGGCCTC-GTCAC primers and served as an internal loading control. We also confirmed the efficacy of tamoxifen-induced recombination in adult mice by assaying Myog mRNA in mice treated with and without tamoxifen following denervation of the tibialis anterior muscle (see below for muscle denervation protocol, satellite cell protocol, RNA isolation protocol, and primers used to assay Myog mRNA levels).
MUSCLE DENERVATION
Muscle denervation was used to induce muscle atrophy and investigate the consequences of muscle denervation on muscle function and gene expression. For muscle denervation experiments, mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Fur covering the lower back to proximal thigh was removed; the region was swabbed with Betadine and a small posterolateral cutaneous incision (1-2 cm) was made beginning near the sciatic notch. The superficial facia was cut and the hamstring and gluteal muscles were separated bluntly to reveal the sciatic nerve. A 1 cm long region of the sciatic nerve was excised and the incision was closed with wound clips. Three to fourteen days later muscles were harvested for molecular and physiological assays.
SATELLITE CELL PROLIFERATION IN DENERVATED MUSCLE AND CELL CULTURE
To assay satellite cell proliferation in denervated muscle, bromodeoxyuridine (BrdU, 50 mg/kg dissolved in 100 ml of 0.9% saline) was intraperitoneally injected daily, beginning at 5 days postdenervation and continuing for the next 8 days. Dissected soleus muscles were embedded in OCT, frozen in liquid nitrogen, sectioned to 10 mm and fixed in 4% paraformaldehyde. Immunofluorescence was performed as previously described [Ramachandran et al., 2010] , using the following primary antibodies: mouse anti-laminin B2, D18 (Developmental Studies Hybridoma Bank, University of Iowa, 1:25 dilution); rat anti-BrdU (Abcam, 1:500 dilution). Secondary antibodies were conjugated to Alexa Fluor 488 or Cy3 and used at 1:500 for anti-mouse and 1:250 for anti-rat. For BrdU detection, sections were pre-treated with 2 N HCl for 20 min at 378C and then soaked in 100 mM sodium borate for 10 min. Following immunohistochemical staining, slides were rinsed with water and allowed to dry in the dark before cover-slipping with 2.5% (w/v) PVA (polyvinyl alcohol)/DABCO (1,4 diazabicyclo (2.2.2)octane). Slides were examined in a Zeiss Axiophot fluorescence microscope equipped with a digital camera. Muscle satellite cells were purified from EDL and soleus muscles to determine if tamoxifen-induced recombination successfully deleted the Myog gene in satellite cells. Muscles were isolated from innervated and 3 day denervated Wt and Myog flox/flox ;CAGGCreER TM mice that were previously treated with tamoxifen as described above. Dissected muscles were incubated in collagenase (0.2% w/v) at 378C for 1.5-2 h, washed 3Â with DMEM and triturated through a wide bore glass pipette that was pre-coated with horse serum and then triturated through a P1000 pipetman blue tip. Muscle fragments in 2-4 ml of DMEM were transferred to a 15 ml Falcon tube and allowed to settle for 10 min. After removing the supernatant, muscle fragments were resuspended in 7 ml of 20% fetal bovine serum, DMEM, and 1Â antibiotics and distributed into tissue culture plates coated with Matrigel. The following day muscle fragments were removed, satellite cells allowed to proliferate and 3-4 days later harvested for RNA isolation and RT-PCR.
MUSCLE DENERVATION AND ELECTRICAL STIMULATION
We used direct stimulation of denervated muscle with extracellular electrodes to examine if Atrogin-1 and MuRF-1 gene expression, like Myog gene expression, is regulated by muscle electrical activity. Denervation and electrical stimulation were carried out on rat soleus muscle as previously described [Goldman et al., 1988] . Briefly, the lower hind limb muscles were bilaterally denervated in anesthetized Sprague Dawley rats by removing a small segment of the sciatic nerve at mid thigh. Stimulating electrodes were implanted into one hind limb and the soleus muscle was stimulated chronically for up to 2 days in 100 Hz trains, 1 s duration, applied once every 100 s. Stimulus pulses within trains were of alternating polarity, their duration was 0.5 ms and their strength was 10-15 mA. At the end of the stimulation period, stimulated and contralateral unstimulated soleus muscles were excised and RNA extracted for RT-PCR.
MUSCLE FORCE, FIBER AREA, AND MASS MEASUREMENTS
To investigate the consequences of muscle denervation and Myog deletion on muscle atrophy, muscle force, area, and mass were measured. Innervated and 14 day denervated soleus and EDL muscles were isolated from adult Wt and tamoxifen treated Myog conditional knockout mice. Suture ties (5-0) were secured around the distal and proximal tendons, and the muscles were carefully removed and placed in a horizontal bath containing buffered mammalian Ringer solution (137 mM NaCl, 24 mM NaHCO 3 , 11 mM glucose, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgSO 4 , 1 mM NaH 2 PO 4 , and 0.025 mM turbocurarine chloride) maintained at 258C and bubbled with 95% O 2 -5% CO 2 to stabilize pH at 7.4. One tendon of the muscle was tied securely to a force transducer (model BG-50, Kulite Semiconductor Products, Leonia, NJ) and the other tendon to a fixed post.
To determine maximum isometric tetanic force ( P o ), muscles were stimulated between two stainless steel plate electrodes. The voltage of single 0.2-ms square stimulation pulses and, subsequently, muscle length were adjusted to obtain maximum twitch force. The muscle length at which maximum twitch force was obtained was measured with calipers to determine the optimal length for force development (L o ). With the muscle held at L o , the force developed during trains of stimulation pulses was recorded, and stimulation frequency was increased until the maximum isometric tetanic force ( P o ) was achieved. For each muscle, optimum fiber length (L f ) was calculated by multiplying L o by previously determined L f /L o ratios for EDL and soleus muscles of 0.45 and 0.71, respectively [Brooks and Faulkner, 1988] . After force measurements, muscles were removed from the bath, the tendons were trimmed, and the muscle was blotted and weighed. Muscles were quick frozen in isopentane cooled with liquid nitrogen and stored at -808C for subsequent histological analyses. Total muscle cross-sectional area (CSA) was calculated by dividing the muscle mass by the product of L f and the density of mammalian skeletal muscle, 1.06 g/cm 3 . Changes in average muscle fiber CSAs after denervation were determined on muscle cryo-sections (14 mm) taken from the mid-region of soleus muscles. Muscle sections were stained with hematoxylin and eosin to identify the borders of individual muscle fibers and the areas of 100 fibers/muscle were determined with ImageJ (NIH). Changes in muscle mass, P o , total CSA, and average fiber area after denervation are expressed relative to corresponding contra lateral innervated muscles (n ¼ 4 for each condition except where identified). Differences between the experimental and Wt samples were assessed by a 2-tailed Student's t test, with the assumption of 2-sample equal variance. Values are expressed as means AE 1 SEM and significance was set a priori at P < 0.05.
IN VIVO MUSCLE ELECTROPORATION
We used electroporation to facilitate DNA uptake by muscle fibers in order to investigate the consequences of Myog overexpression on Atrogin-1 and MuRF-1 gene expression and Atrogin-1 promoter activity. For in vivo Myog overexpression, 5 mg pCS2:EGFP plasmid (gift from D. Turner, University of Michigan, Ann Arbor) and either 20 mg of pCS2:Myog [Tang et al., 2001] or control empty vector (pCS2) were injected into innervated soleus muscles of anesthetized adult mice. For in vivo analysis of Atrogin-1 promoter activity, 15 mg of pCS2:Myog or pCS2 along with 5 mg of pCS2:EGFP, 5 mg of the Atrogin-1:luciferase reporter plasmid [Sandri et al., 2004] and 5 mg of the normalization vector, ubC:Renilla luciferase (gift from M. Uhler, University of Michigan, Ann Arbor), were injected into left and right hindlimb innervated EDL or soleus muscles. Plasmid uptake was facilitated by placing square flat stainless steel electrodes, coated with ultrasound transmission gel, on each side of the leg and using a BTX840 square wave electroporator to deliver eight pulses of 140 V/cm of 60-ms duration with an interval of 100 ms. Mice were allowed to recover 12 days before isolation of electroporated GFP þ fibers (for Myog over-expression in innervated muscle) or before denervation (for Atrogin-1 promoter analysis). Electroporated GFP þ fibers were identified under a stereomicroscope (Leica MZFLIII) equipped with fluorescence optics. GFP þ fibers were dissected in ice-cold phosphate-buffered saline (PBS) and then immediately lysed for RNA and luciferase assays. All experiments were performed in triplicate and results are expressed as mean AE SEM. RNA levels were assayed by RT-PCR using the following primers: g-Actin forward 5 
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RNA ISOLATION AND REAL-TIME PCR Total RNA was isolated using TRIzol (Invitrogen). The Turbo DNase Kit (Ambion) was used to remove residual DNA and total RNA was quantified spectrophotometrically. One microgram of total RNA was used to generated cDNA with oligo (dT) primers and Superscript II reverse transcriptase (Invitrogen). Real-time PCR was performed with SYBR green mix (1:20,000 SYBR green) on an iCycler iQ realtime detection system (BioRad) according to the manufacturer's instructions. Each reaction was performed in triplicate on at least three samples for each condition in a volume of 20 ml. The specificity and efficiency of the primers used in real-time PCR were first verified by 1% agarose gel electrophoresis. PCR cycles were 958C for 5 min, 958C for 30 s, 588C for 30 s, and 728C for 30 s (total 40 cycles). 
WESTERN BLOTS
Western blots were used to investigate if denervation-dependent Myog protein induction preceded denervation-dependent induction of atrophy-related genes. Western blotting was performed as previously described [Kostrominova et al., 2000] amplify exon 1, we find that our regimen of tamoxifen treatment results in its deletion (Fig. 1, top panel) . Because Myog gene expression is low in innervated muscle and highly induced following muscle denervation [Eftimie et al., 1991; Kostrominova et al., 2000; Tang et al., 2009] , one can also test the efficacy of tamoxifen treatment by assaying Myog RNA levels in innervated and denervated muscle. For this analysis we injected Myog flox/flox ;CAGG-CreER TM mice with tamoxifen or vehicle and then the left lower hindlimb muscles were denervated by cutting the sciatic nerve. Seven days later, innervated (right hindlimb) and denervated (left hindlimb) muscles were dissected and Myog and g-actin mRNA levels assayed by RT-PCR. We found that innervated muscles of control and tamoxifen-treated mice expressed very low to undetectable levels of Myog mRNA (Fig.  1, bottom panel) . In contrast, muscle denervation dramatically induced Myog expression only in control mice that did not receive tamoxifen, while Myog expression remained undetectable in denervated muscles of mice that received tamoxifen (Fig. 1, bottom  panel) . We also isolated satellite cells from innervated and Left lower hindlimb muscles were denervated by sciatic nerve transection and 3-7 days later innervated and denervated muscles were dissected. Genomic DNA was isolated for PCR amplification of exon 1 from the Myog gene (top panel (Fig. 1, middle panel) .
MYOG CONTRIBUTES TO MUSCLE MASS, FORCE, AND CSAS
We next deleted Myog in adult mice and denervated the left lower hindlimb muscles for 14 days; a similar denervation protocol was performed on Wt mice for comparison. During preliminary experiments we determined that 2 weeks of muscle denervation had no significant effect on either muscle mass or maximum isometric force in the contralateral innervated soleus or EDL muscle of denervated animals when compared to muscles isolated from age and weight matched mice whose muscles remained innervated ( Fig. 2A and B) . Consequently, all subsequent experiments were performed making use of the contralateral innervated limb as the internal control. Fast fiber-type EDL and slow fiber-type soleus muscles were then dissected for measurements of muscle mass, force, and CSA. Consistent with that reported by others [Grossman et al., 1998 ], we found that the slow soleus muscle atrophied to a greater extent (44% loss in muscle mass) than the fast EDL muscle (26% loss in muscle mass) (Fig. 2C) . Interestingly, soleus and EDL muscle atrophy was attenuated in Myog knockout mice where they lost only about half as much mass as the Wt animals (22% loss of mass for soleus and 14% loss in mass for EDL) (Fig. 2C ). Similar to muscle mass measurements, the maximum isometric force developed by denervated EDL and soleus muscles was significantly less than the contralateral innervated muscles (Fig. 2D) . However, in this case there was no significant difference between Wt and Myog knockout animals in the magnitude of the force decrease in EDL muscles ($20%), while in soleus muscles the decreases in maximum isometric force were much greater for Wt than Myog knockout mice (42% vs. 22%, respectively) (Fig. 2D) . In general, these data are consistent with the hypothesis that Myog plays a regulatory role during the development of muscle atrophy. The lack of a significant effect of Myog knockout on the development of maximum isometric force in EDL muscles is perplexing. We speculate that this is due, in part, to the relatively small amount of atrophy observed in the EDL ) mice were denervated for 14 days. Innervated and denervated EDL and soleus muscles were then dissected and muscle mass (A) and force (B) assayed. Reported is the denervated mass and force relative to the contralateral innervated muscle. Note that Myog deletion attenuates denervation-dependent loss in muscle mass and force, especially for the soleus muscle. Error bars are standard error of the mean (n ¼ 4). muscles which limited our ability to resolve differences in force. Because of the much larger differences in both mass and maximum force development in the denervated soleus muscles of Wt and Myog knockout mice, we chose to focus our experiments on this muscle.
When mass and force values were used to deduce muscle CSAs, we also found a statistically significant attenuation of denervationinduced atrophy in the soleus muscle (Fig. 3A) . To more carefully examine this, we sectioned soleus muscle from innervated and 14 day denervated Wt and Myog knockout mice and quantified fiber CSAs. Consistent with our force and mass measurements, this analysis indicated that individual fibers atrophied less in the absence of Myog (Fig. 3B ). Calculations of CSAs from 100 random fibers indicated a denervation-dependent reduction in fiber CSA of 51.5 AE 3.9% in Wt soleus muscle and only 34 AE 3.4% reduction in soleus muscle fibers lacking Myog expression.
We next investigated if Myog deletion had a consequence on satellite cell proliferation and fusion with denervated muscle fibers which may account for preservation of muscle mass in Myog knockout animals. For these experiments we treated Wt and Myog knockout mice with BrdU after muscle denervation. Two weeks later soleus muscles were monitored for BrdU incorporation into denervated muscle fibers. Although, we were able to detect scattered BrdU labeled satellite cells in the interstitial regions of Wt animals ($22 AE 4 BrdU þ cells/soleus muscle, n ¼ 3) there was no BrdUlabeled nuclei in Myog knockout animals (Fig. 3C) . Therefore, increased satellite cell proliferation and fusion cannot explain the maintenance of muscle mass in Myog knockout animals.
MYOG, ATROGIN-1, AND MURF-1 GENE EXPRESSION ARE COORDINATELY REGULATED BY MUSCLE ELECTRICAL ACTIVITY Knockout mice lacking either Atrogin-1 or MuRF-1 exhibit reduced denervation-induced muscle atrophy compared to Wt mice [Bodine et al., 2001a] . Therefore, it is possible that Myog mediates its effects on muscle atrophy by controlling Atrogin-1 and MuRF-1 gene expression. Consistent with this idea, Atrogin-1 and MuRF-1 mRNAs, like Myog mRNA, are induced following muscle denervation (Fig. 4) [Bodine et al., 2001a] and Myog mRNA and protein induction appears to precede Atrogin-1 and MuRF-1 mRNA induction (Fig. 4) . Denervation dependent gene regulation can result from loss of trophic factors released from the motor neuron [Mejat et al., 2003] ; however, Myog gene expression is largely Adult hind limb muscles were denervated and 5 days later BrdU was injected (once daily) into animals for the next 8 days. Soleus muscles were collected and stained for laminin (green) to identify the extracellular matrix, BrdU (red) to identify dividing cells and DAPI (blue) to visualize nuclei.
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regulated by muscle electrical activity independent of motor innervation [Eftimie et al., 1991; Buonanno et al., 1992] . Interestingly, direct stimulation of denervated rat soleus muscle with extracellular electrodes rapidly suppressed not only Myog, but also Atrogin-1 and MuRF-1 gene expression (Fig. 5) . Within 6 h following stimulation of the denervated soleus muscle Myog, Atrogin-1, and MuRF-1 mRNAs are dramatically reduced and by 24-48 h of electrical stimulation these mRNAs approach or are below basal levels. These data suggest that all three of these mRNAs are regulated by muscle electrical activity and are consistent with the idea that Myog regulates Atrogin-1 and MuRF-1 gene expression.
MYOG REGULATES ATROGIN-1 AND MURF-1 GENE EXPRESSION IN DENERVATED MUSCLE
To directly test the idea that Myog controls atrophy-related gene expression in denervated muscle, we compared Atrogin-1 and MuRF-1 mRNA expression in Wt and Myog null mice. We also assayed FoxO3 expression in these mice because FoxO3 contributes to denervation-induced muscle atrophy [Sandri et al., 2004; Sandri et al., 2006; Mammucari et al., 2007; Zhao et al., 2007] , at least in part, by stimulating Atrogin-1 gene expression [Sandri et al., 2004] . Therefore, Myog may act on Atrogin-1 and MuRF-1 gene expression directly or indirectly via regulated expression of FoxO3. To test these possibilities we compared denervation-dependent gene expression in Wt and Myog null mice. We chose 3 days post-denervation for these assays because this is when Atrogin-1 RNA levels are reported to be highest [Sacheck et al., 2007] . Real-time PCR showed that muscle denervation induced Atrogin-1 mRNA by about 5.5-fold, MuRF1 mRNA by almost 4-fold, and Myog mRNA by about 27-fold (Fig. 6) . Interestingly, these genes were not induced in Myog null mice (Fig. 6) . In contrast, FoxO3 mRNA expression does not appear to be significantly regulated by muscle denervation (Fig. 6 ). These data are consistent with the idea that Myog mediates denervationdependent induction of Atrogin-1 and MuRF-1 gene expression. Because Atrogin-1 gene expression was more robustly regulated by muscle activity than MuRF-1 gene expression, we focused on this gene to further examine its regulation by Myog. To investigate if Myog can induce Atrogin-1 gene expression in vivo, we electroporated adult innervated soleus muscle with pCS2:Myog and pCS2:EGFP expression vectors. Twelve days following electroporation, soleus muscles were isolated, GFP-expressing fibers dissected and RNA isolated for analysis of Myog, Atrogin-1, and gactin mRNA levels by real-time PCR. This analysis showed that Myog over-expression induced Atrogin-1 mRNA levels (Fig. 7A) . These results suggest that Myog may directly activate the Atrogin-1 promoter. Indeed, inspection of the 3.5 kb Atrogin-1 promoter identified eight putative Myog binding sites (E-boxes, CANNTG) (Fig. 7) . Interestingly, four of these sites conform to previously identified Myog binding sites (CACCTG, CAGCTG) that have been shown to be necessary for denervation-dependent activation of the muscle-specific nAChR and MuSK promoters . Cotransfection of HEK 293 cells with an Atrogin-1:luciferase expression vector and pCS2-Myog showed Myog regulates Atrogin-1 promoter activity. In addition, a series of promoter deletions indicated reduced promoter activity in both HEK 293 cells overexpressing Myog (Fig. 7B ) and in denervated soleus muscle (Fig. 7C) that presumably reflects the reduction in Myog binding sites. Deletion of distal E-boxes located between À1 and À3.5 kb from the translation start site had a large consequence on the ability of Myog to activate Atrogin-1 promoter activity in denervated muscle (Fig.  7C ) and may suggest that these distal E-boxes play a more significant role than the more proximal E-boxes in denervationdependent Atrogin-1 gene activation. Taken together, these data are consistent with the idea that Myog mediates its effects on muscle atrophy by directly regulating Atrogin-1 promoter activity.
DISCUSSION
The main finding from this study is that Myog expression contributes to denervation-induced muscle atrophy. Myog is best known for its role in muscle fiber formation during early development where it is necessary for myoblast differentiation and fusion [Hasty et al., 1993; Venuti et al., 1995; Vivian et al., Fig. 4 . Denervation-dependent regulation of Myog, Atrogin-1 and MuRF-1 gene expression. Lower hindlimb muscles of adult mice were denervated for the indicated times. Real-time PCR was used to quantify Myog, Atrogin-1, MuRF-1, and Actin mRNA levels. RNA levels were normalized to Actin RNA levels and then normalized to innervated RNA levels. Western blots were used to assay denervation-dependent Myog protein induction. Myosin protein levels were used to reveal differences in the amount of protein loaded onto the gel. Error bars are standard error of the mean (n ¼ 3). 1999]. Postnatally, Myog expression is suppressed by muscle innervation in an activity-dependent manner [Eftimie et al., 1991; Buonanno et al., 1992] . Denervation of adult muscle induces Myog expression where it plays an important role in mediating both denervation-dependent gene induction and suppression [Tang et al., 2004; Tang et al., 2009] . Genes that are regulated, either directly or indirectly, by Myog include those involved in synapse formation, muscle fiber determination and muscle metabolism Tang et al., 2009] .
We were intrigued by the large induction in Atrogin-1 gene expression following muscle denervation [Sacheck et al., 2007] and tested the idea that denervation-dependent Myog expression mediated this induction. Indeed our data suggests that Myog regulates Atrogin-1 gene expression in denervated muscle which, along with previously published data showing Atrogin-1 expression contributes to muscle atrophy [Bodine et al., 2001a] , is consistent with the hypothesis that Myog contributes to denervation-induced muscle atrophy.
We took advantage of mice that conditionally express Myog to investigate its role in denervation-induced muscle atrophy. Previous studies had shown that Myog is necessary for muscle fiber formation during embryonic periods of development while loss of Myog postnatally has little consequence on muscle growth [Hasty et al., 1993; Venuti et al., 1995; Vivian et al., 1999; Knapp et al., 2006] . We deleted Myog in adult mice and found that these mice exhibited less denervation-induced muscle atrophy than Wt controls. This effect was most pronounced for the slow soleus muscle and unremarkable for the fast EDL muscle. This is not too surprising since previous studies have documented that slow muscle fibers are more prone to atrophy than fast muscle fibers [Grossman et al., 1998 ] and may suggest that Myog and its targets, such as Atrogin-1, are differentially regulated in fast and slow muscle fibers. Indeed basal ) mice were denervated for 3 days. Innervated and denervated soleus muscles were then dissected and RNA extracted for RT-PCR (&) . Ethidium bromide ( ) stained gel shows the relative transcript levels. Real-time PCR was used to quantify these levels which are shown in the graph. Note that Myog deletion blocks denervation-dependent induction of Atrogin-1, MuRF-1, and Myog mRNA expression while FoxO3 mRNA expression is slightly increased in following muscle denervation. Error bars are standard error of the mean (n ¼ 3). Lower hind limbs of adult rats were bilaterally denervated and stimulating electrodes were implanted into one hind limb. Denervated soleus muscles were electrically stimulated for 0-48 h. RNA was isolated from innervated, 3-day denervated and 3-day denervated/stimulated soleus muscle and assayed by RT-PCR (representative ethidium bromide stained agarose gel is shown) and real-time PCR (graph). Note that direct electrical stimulation of soleus muscle rapidly suppressed denervation-dependent Myog, Atrogin-1, and MuRF-1 gene expression. Experiments were repeated twice with almost identical results.
Myog expression is known to be higher in soleus compared to EDL [Hughes et al., 1993; Voytik et al., 1993] . However, whether this basal expression contributes to the differential atrophy noted in soleus and EDL muscles is not clear.
We investigated if the protection against muscle atrophy is a result of increased satellite cell proliferation and fusion with existing muscle fibers in Myog knockout mice. Surprisingly, we found that denervation-induced satellite cell proliferation is reduced in Myog knockout mice and therefore, cannot account for the maintenance of muscle mass or CSA in their denervated fibers. It has been previously suggested that contact between muscle and nerve, independent of muscle activity, is sufficient to suppress satellite cell proliferation [Hyatt et al., 2003] . Our data suggests that Myog may be a factor that mediates this effect of the nerve on muscle satellite cells.
Of the genes previously shown to participate in muscle atrophy, we identified Atrogin-1 as a putative Myog target. Data supporting this idea include: (1) lack of Atrogin-1 induction following muscle denervation in Myog knockout mice; (2) Myog over-expression in innervated muscle induced Atrogin-1 gene expression; and (3) Myog-dependent and denervation-dependent activation of the Atrogin-1 promoter in tissue culture cells and soleus muscle, respectively. Thus, Myog appears to mediate its effect on muscle atrophy, at least in part, via activation of Atrogin-1 gene expression. MuRF-1 mRNA was also induced in denervated soleus muscle of Wt mice but not in Myog null mice which suggests Myog also contributes to muscle atrophy by controlling denervation-dependent induction of MuRF-1.
Previous studies have suggested that Atrogin-1 and MuRF-1 gene expression is regulated by the forkhead transcription factor, FoxO3 [Bodine et al., 2001b; Sandri et al., 2004] . FoxO3 activity is induced by the PI3K/AKT signaling cascade and inhibited by PGC-1a [Bodine et al., 2001b; Sandri et al., 2004; Sandri et al., 2006] . In addition, NF-kB signaling also impinges on muscle atrophy, at least in part, by increased expression of MuRF-1 [Cai et al., 2004; Mourkioti et al., 2006] . There are no studies linking denervationdependent Myog gene expression to FoxO3 or NF-kB signaling pathway, suggesting that denervation-dependent Myog gene activation may be under the control of other signaling cascades.
The mechanism by which the Myog gene is activated in denervated muscle is of interest because it may represent a new target for reducing the detrimental consequences of muscle denervation following injury or disease. We and others have previously reported that denervation-dependent Myog gene induc- [Sandri et al., 2004] , pCS2:EGFP to identify electroporated fibers and ubC:Renilla luciferase for normalization. 12 days postelectroporation the left hindlimb muscle was denervated for 3 days and then GFP þ fibers were dissected from innervated and denervated electroporated muscles for luciferase assays. Black ovals in the promoter cartoon indicate E-boxes (CANNTG) that conform to the consensus Myog binding E-box, while grey ovals represent E-boxes that do not conform to this consensus sequence. Note the stimulation of Atrogin-1 promoter activity by Myog overexpression and muscle denervation and that as one deletes promoter sequences harboring E-boxes, Myog-dependent and denervation-dependent Atrogin-1 promoter activation is reduced. Experiments were performed in triplicate. Error bars are standard error of the mean (n ¼ 3).
tion is accompanied by translocation of HDAC4 to the nucleus and that HDAC4 expression is necessary for Myog gene expression [Cohen et al., 2007; Tang et al., 2009] . HDAC4 stimulates Myog gene expression by suppressing expression of the Myog gene transcriptional co-repressors, Dach2 and MITR [Mejat et al., 2005; Cohen et al., 2007; Tang et al., 2009] . Myog also stimulates HDAC4 gene expression, reinforcing the continued expression of these genes in denervated muscle [Tang et al., 2009] . Interestingly, while this article was in preparation it was reported that not only Myog, but also HDAC4 and 5 contribute to denervation-induced muscle atrophy [Moresi et al., 2010] . This latter study also came to the conclusion that Myog mediates its effects on muscle atrophy by regulating Atrogin-1 and MuRF1 gene expression. The HDAC4/5-Dach2-Myog signaling cascade impinges on a large number of genes induced in denervated muscle that influence muscle fiber metabolism, synapse formation, and atrophy and therefore represents a potential target for reducing the detrimental consequences of muscle atrophy following injury or disease. However, because inhibition of this signaling pathway would contribute to maintaining a pattern of gene expression more like innervated muscle and because innervated muscle is resistant to reinnervation, inhibition of this signaling pathway in denervated muscle may preserve muscle mass at the expense of enhancing muscle reinnervation.
